证券代码：002001 证券简称：新和成 公告编号：2025-007 浙江新和成股份有限公司 第九届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）第九届监事会第七次会议于 2025 年 4 月 1 日以电子邮件方式发出会议通知，于 2025 年 4 月 11 日在公司总 部会议室召开。应出席监事五名，实际出席五名。本次会议出席人数、召开程序、 议事内容均符合《公司法》和《公司章程》的规定。会议由监事会主席吕国锋先 生主持，经表决形成决议如下： 一、会议以 5 票同意，0 票反对，0 票弃权审议通过《2024 年度监事会工作 报告》，该议案尚需提交股东大会审议。 全文详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）刊登的公告。 二、会议以 5 票同意，0 票反对，0 票弃权审议通过《2024 年年度报告及摘 要》，该议案尚需提交股东大会审议。 《 2024 年 年 度 报 告 》 全 文 详 见 公 司 同 日 在 巨 潮 资 讯 网 （http://www.cni ...

证券代码：002001 证券简称：新和成 公告编号：2025-006 浙江新和成股份有限公司 第九届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）第九届董事会第十一次会议 于 2025 年 4 月 1 日以电子邮件方式发出会议通知，于 2025 年 4 月 11 日在公司 总部会议室召开，应出席董事 11 名，实际出席董事 11 名，其中董事周贵阳委托 董事石观群进行投票，独立董事季建阳委托独立董事沈玉平进行投票。公司监事 和高级管理人员列席了会议。符合《公司法》和《公司章程》的规定。会议由董 事长胡柏藩先生主持，经表决形成决议如下： 一、会议以 11 票同意，0 票反对，0 票弃权审议通过《2024 年度总经理工作 报告》。 二、会议以 11 票同意，0 票反对，0 票弃权审议通过《2024 年度董事会工作 报告》的议案，该议案尚需提交股东大会审议。公司独立董事季建阳、沈玉平、 万峰、王洋向董事会提交了独立董事述职报告，并将在公司 2024 年年度股东大 会上述职。 全文详见公司同日在巨 ...

证券代码：002001 证券简称：新和成 公告编号：2025-009 浙江新和成股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 浙江新和成股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开的 第九届董事会第十一次会议审议通过《2024 年度利润分配预案》，该事项尚需提 交 2024 年年度股东大会审议。 二、2024 年度利润分配预案的基本情况 1、本次利润分配方案的基本内容 经天健会计师事务所（特殊普通合伙）审计，2024 年度公司实现净利润 5,896,870,207.59 元，其中归属于母公司股东的净利润 5,868,545,988.62 元。2024 年母公司实现净利润 2,726,593,387.44 元，加上年初未分配利润 5,137,599,917.63 元，减去 2024 年度分配股利 1,383,039,756.00 元，2024 年度提取盈余公积 0 元， 经决算，2024 年末可供股东分配的利润为 6,481,153,549.07 元。 若在分配方案实 ...

Financial Performance - The company's operating revenue for 2024 reached ¥21,609,592,228.45, representing a 42.95% increase compared to ¥15,116,537,003.30 in 2023[17]. - Net profit attributable to shareholders for 2024 was ¥5,868,545,988.62, a significant increase of 117.01% from ¥2,704,238,767.54 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥5,828,938,494.33, up 122.97% from ¥2,614,210,640.58 in the previous year[17]. - Basic earnings per share for 2024 were ¥1.91, reflecting a 119.54% increase from ¥0.87 in 2023[17]. - The company's total assets at the end of 2024 amounted to ¥42,989,132,470.97, a 9.79% increase from ¥39,156,246,864.67 at the end of 2023[17]. - The net assets attributable to shareholders increased by 18.22% to ¥29,324,997,728.95 from ¥24,804,662,320.99 in 2023[17]. - Cash flow from operating activities for 2024 was ¥7,073,064,183.33, a 38.16% increase compared to ¥5,119,370,863.32 in 2023[17]. - The weighted average return on equity rose to 21.78%, an increase of 10.54 percentage points from 11.24% in 2023[17]. Revenue Breakdown - Revenue from the pharmaceutical and chemical sector accounted for ¥19.84 billion, which is 91.82% of total revenue, with a year-on-year growth of 43.81%[59]. - The nutrition products segment generated ¥15.05 billion, making up 69.67% of total revenue, with a significant increase of 52.58% compared to the previous year[59]. - The company’s total revenue for 2024 reached ¥21.61 billion, representing a 42.95% increase compared to ¥15.12 billion in 2023[59]. - The company achieved a 54.57% increase in foreign sales, amounting to ¥12.05 billion, which represents 55.78% of total revenue[59]. Market Outlook - The global demand for methionine is projected to increase by 6.3% in 2024, with domestic demand in China expected to rise by 4.7%[28][29]. - The vitamin market in China is expected to produce approximately 420,000 tons in 2024, accounting for 85.9% of global production, with prices recovering from a low point[27]. - The revenue of the fragrance and flavor industry in China is expected to reach ¥50 billion by 2025, with significant export contributions[30]. Research and Development - The company maintained R&D investment at over 5% of revenue for several consecutive years, focusing on key technologies with strategic economic impact[47]. - The company is focusing on expanding its core technology platforms in the fine chemical industry, particularly in nutrition, flavors, and new materials[26]. - The company is advancing the development of continuous reaction and pipeline reaction technologies to enhance production efficiency and competitiveness[72]. - The company has successfully achieved the production of vitamins B5 and B12 through optimized fermentation processes, positioning itself at the forefront of green manufacturing[72]. - R&D investment reached ¥1,036,161,740.50 in 2024, marking a 16.71% increase from ¥887,801,475.02 in 2023, while the ratio of R&D investment to operating revenue decreased by 1.08 percentage points to 4.79%[74]. Environmental Compliance - The company has established a comprehensive wastewater treatment system, ensuring effective collection and incineration of wastewater to reduce emissions[185]. - The company is committed to higher environmental standards and exploring eco-friendly production methods in response to evolving environmental regulations[115]. - The company has successfully renewed pollution discharge permits for multiple subsidiaries, valid until 2029[180]. - All reported pollutants from the companies were within the regulatory limits, indicating compliance with environmental standards[182]. Governance and Management - The company emphasizes compliance and transparent information disclosure, ensuring all shareholders have equal access to information[126]. - The company has a robust organizational structure with independent operational departments, ensuring no overlap with the controlling shareholder's functions[134]. - The company has appointed independent directors with diverse backgrounds, including expertise in economics, management, and law, enhancing governance[143]. - The company has a clear performance guidance strategy for the upcoming fiscal year[148]. Employee and Shareholder Relations - The company distributed a cash dividend of 4.50 RMB per 10 shares, totaling 1,383,039,756.00 RMB (including tax) based on a share base of 3,073,421,680 shares[163]. - The company has a competitive compensation structure that includes basic salary, performance pay, and benefits, aimed at enhancing employee satisfaction and loyalty[161]. - The total remuneration for directors, supervisors, and senior management amounted to CNY 31.62 million[153]. Strategic Initiatives - The company plans to accelerate its internationalization strategy and enhance local operational capabilities to navigate macroeconomic uncertainties[110]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million allocated for potential deals[117]. - The company aims to strengthen its nutrition business, focusing on integrated and market-coordinated operations to enhance product competitiveness[102].

Financial Performance - The company expects a net profit attributable to shareholders of 1.8 billion to 1.9 billion CNY for Q1 2025, representing a year-on-year increase of 107% to 118% compared to 869.62 million CNY in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is also projected to be between 1.8 billion to 1.9 billion CNY, reflecting a growth of 110% to 122% from 857.47 million CNY in the previous year [3]. - Basic earnings per share are anticipated to be between 0.59 CNY and 0.62 CNY, up from 0.28 CNY per share in the same quarter last year [3]. Business Strategy - The increase in performance is attributed to higher sales volume and prices of key products in the nutrition segment compared to the previous year [5]. - The company will continue to focus on integrated, series, and collaborative development strategies, emphasizing "Chemical +" and "Biological +" main strategies [5]. - Future plans include enhancing application research and service capabilities, with a focus on nutrition products, flavors, high polymer new materials, and raw pharmaceutical materials [5]. - The company aims to strengthen its global marketing network and promote sustainable high-quality development while exploring opportunities in strategic emerging industries such as plant protection, new energy, energy conservation, and environmental protection [6]. Investment Risks - The financial data in the earnings forecast has not been audited by registered accountants, and investors are advised to pay attention to investment risks [4][7].

证券代码：002001 证券简称：新和成 公告编号：2025-010 浙江新和成股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、浙江新和成股份有限公司（以下简称"公司"）第九届董事会第十一次 会议审议通过《关于回购公司股份方案的议案》，拟以自有资金或回购专项贷款 以集中竞价交易的方式回购公司部分社会公众股份，回购股份用于实施股权激励 计划或员工持股计划。本次回购金额区间为 30,000 万元-60,000 万元，回购价格 不超过人民币 32 元/股。按本次回购资金总额上下限人民币测算，预计回购股份 区间为 9,375,000 股-18,750,000 股，占公司总股本的比例区间为 0.31%-0.61%。 具体回购股份的数量以回购期满时实际回购的股份数量为准。本次回购股份期限 为自董事会审议通过本回购方案之日起 12 个月。 2、风险提示： （1）本次回购方案可能面临因回购期限内公司股票价格持续超出回购价格 上限等原因，导致本次回购方案无法实施或只能部分实施的风险。 （2）本次股份回购用于股权激励计 ...

Group 1 - The company Xinhecheng has received approval for its isophorone diisocyanate (IPDI) project, with a planned capacity of 21,000 tons, and the first phase of the project has already been put into production [1] - The overall capacity planning for the HA project includes 103,000 tons of hexamethylene diisocyanate (HDI), 21,000 tons of IPDI, 20,000 tons of biuret, 83,000 tons of HDI trimer, 40,000 tons of isophorone diamine (IPDA), and by-products including 100,000 tons of hydrochloric acid and 6,400 tons of ammonium sulfate [1] - The first phase of the project includes the construction of production facilities for IPDA, HDI, IPDI, and biuret, supported by public utilities such as phosgene synthesis and CO₂ purification facilities, as well as environmental protection facilities [1] Group 2 - As of March 2025, products such as HDI, ADI, and IPDA have already been put into production, with annual capacities of 20,000 tons for IPDA, 4,000 tons for ADI, and 3,000 tons for HDI [2] - The domestic IPDI market reacted quickly to the supply disruption caused by the force majeure declarations from global chemical giants Evonik and Covestro, with prices rising from 34,000-38,000 yuan/ton to 35,000-39,000 yuan/ton, reflecting an average daily increase of approximately 1,000 yuan/ton [2] - IPDI is a cyclic diisocyanate that plays a significant role in water-based polyurethane applications and is widely used in plastics, adhesives, pharmaceuticals, and fragrances, indicating potential short-term market opportunities for domestic IPDI producers [2]

整体来看，新和成此次回购不仅有助于优化资本结构、提振市场信心，也进一步巩固了其作为全球维生 素行业领军者的地位。(厉平) 本次回购，体现出公司管理层对未来持续稳定发展的坚定信心，也有助于切实维护全体投资者的利益， 进一步增强市场信心。值得一提的是，控股股东新和成控股曾于2022年、2023年连续两次增持公司股 份，合计金额达6.88亿元，增持比例超过总股本的1%。此外，公司董事长胡柏藩及多位高管此前亦持 续增持公司股份，且从未减持，展现了对公司长期价值的高度认可。 4月8日，新和成（002001）发布公告称，公司实际控制人、董事长胡柏藩提议通过集中竞价交易方式回 购股份，回购资金总额在3亿元至6亿元之间。此次回购的股份将在未来适当时机用于股权激励或员工持 股计划，体现公司对员工的激励机制与"共享公司发展成果"理念的积极践行。 在国际环境方面，尽管近期美国推行"对等关税"政策，但新和成的主要维生素系列产品——包括VE、 VA、VC、VAD3、VB系列及辅酶Q10系列产品，均被列入豁免清单，不会对公司生产经营造成重大影 响。 新和成是全球领先的维生素生产企业之一，主营业务涵盖营养品、香精香料、高分子新材料和原料药 ...

证券代码：002001 证券简称：新和成 公告编号：2025-005 二、提议回购股份的原因和目的 新和成自成立以来便专注于精细化工，坚持"创新、人和、竞成"的价值观， 秉持"一体化、系列化、协同化"的发展思路，专注技术创新，加快发展新质生 产力，实现公司的稳健经营和快速可持续发展。 目前公司主营业务与财务状况良好。基于对公司未来持续稳定发展的信心和 长期投资价值的认可，为切实维护公司全体投资者利益，增强投资者信心，同时 为了不断完善公司长效激励机制，充分调动公司员工的积极性，有效地将股东利 益和公司利益紧密结合在一起，推进公司长远、稳定、持续的发展，在综合考虑 公司财务状况、经营状况以及未来盈利能力的情况下，公司实际控制人、董事长 胡柏藩先生提议公司通过集中竞价方式回购部分公司股份，并在未来适宜时机将 前述回购股份用于股权激励或员工持股计划。 三、提议内容 浙江新和成股份有限公司 关于实际控制人、董事长提议回购公司部分股份的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"或"新和成"）于 2025 年 4 ...

智通财经4月8日电，新和成(002001.SZ)公告称，公司实际控制人、董事长胡柏藩提议公司通过集中竞 价方式回购部分公司股份，回购资金总额为3亿元-6亿元。回购股份将用于股权激励或员工持股计划， 并在未来适宜时机使用。回购价格不超过董事会通过回购股份决议前30个交易日公司股票交易均价的 150%。胡柏藩承诺将积极推动公司尽快召开董事会审议回购股份事项。 新和成：实际控制人、董事长提议3亿元至6亿元回购公司部分股份 ...